ArticleJAAD case reports2022
Review of dupilumab-associated inflammatory arthritis: An approach to clinical analysis and management.
Article in JAAD case reports, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 15 papers, 1 of them a synthesis that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
15 citing papers in PubMed, 1 synthesis or guideline pooled it.
- Real-World Evidence of Tralokinumab Effectiveness and Safety: A Systematic Review and Meta-analysis.American journal of clinical dermatology · 2025Pooled it
- Longitudinal Proteomic Signatures of Dupilumab and Tralokinumab Treated Atopic Dermatitis Patients.Clinical and translational allergy · 2026Article
- Dupilumab-Induced Myalgia and Enthesitis in a Pediatric Patient Treated for Severe Atopic Dermatitis.Cureus · 2025Article
- Long-term outcomes of dupilumab therapy in severe asthma: A retrospective, multicenter, real-world study.The journal of allergy and clinical immunology. Global · 2025Article
- A case of systemic contact dermatitis associated with a peritoneal dialysis catheter and treated with dupilumab.CEN case reports · 2025Article
- T cell immunophenotypes and IgE responses in patients with moderate-to-severe atopic dermatitis receiving dupilumab.Clinical and translational allergy · 2025Article
- Granulomatous hyperinflammatory state induced by dupilumab treatment for eosinophilic esophagitis.The journal of allergy and clinical immunology. Global · 2024Article
- A real-world study of dupilumab in patients with atopic dermatitis including patients with malignancy and other medical comorbidities.JAAD international · 2024Article
- A retrospective multicenter case series of real-world tralokinumab use in dupilumab-experienced patients.JAAD case reports · 2024Article
- Targeted Systemic Therapies for Adults with Atopic Dermatitis: Selecting from Biologics and JAK Inhibitors.American journal of clinical dermatology · 2024Review
- Joint pain in patients with atopic dermatitis receiving treatment with dupilumab: A US nationwide cohort study.Journal of the American Academy of Dermatology · 2024Article
- Dupilumab-Associated Arthritis: A Dermatology-Rheumatology Perspective.American journal of clinical dermatology · 2023Article
- Biologic Versus Small Molecule Therapy for Treating Moderate to Severe Atopic Dermatitis: Clinical Considerations.The journal of allergy and clinical immunology. In practice · 2023Review
- Risks and safety of biologics: A practical guide for allergists.The World Allergy Organization journal · 2023Review
- Adverse effects of biologics used to treat asthma.Therapeutic advances in respiratory diseaseReview
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
3 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
PubMed holds no abstract for this paper.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.